| Breast Cancer |
1 |
1 |
| Advanced and Metastatic Breast Cancer |
0 |
0.85 |
| HER2-Negative Breast Cancer |
0 |
0.8 |
| Cancer |
0 |
0.71 |
| Breast |
0 |
0.65 |
| Genomic Medicine |
0 |
0.43 |
| Toxicology |
0 |
0.43 |
| Pregnancy |
0 |
0.3 |
| Endocrine Therapy |
0 |
0.23 |
| Selective Estrogen Receptor Modulators |
0 |
0.12 |
| Chemotherapy |
0 |
0.07 |
| Ovarian Ablation |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Tumor |
0 |
0.07 |
| Aromatase Inhibitors |
0 |
0.03 |
| Birth |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Estrogen |
0 |
0.03 |
| Healthcare and Medical Technology |
0 |
0.03 |
| Lymph Node |
0 |
0.03 |
| Texas |
0 |
0.03 |
| Virginia |
0 |
0.03 |